EUVIMEDEUVIMED entdecken
Crossref

Removal of deferrals for variant Creutzfeldt–Jakob disease risk: Impact on new and previously deferred donors

Mindy Goldman iD, David McKee, Shane Smith, Sheila F O'Brien iD

Vox Sanguinis · 2025-06 · 120 (6) · 635-638

DOI: 10.1111/vox.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 24.03.2025. Verfasst von Mindy Goldman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Canadian Blood Services, Medical Affairs and Innovation, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome, Blood Donors, Donor Selection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Concern over variant Creutzfeldt–Jakob disease (vCJD) led to the deferral of donors who had resided in the United Kingdom since January 1980. This deferral was implemented in 1999 and subsequently modified to include other countries. Some deferrals were removed in February 2022; deferrals for the United Kingdom, Ireland and France were removed on 22 November 2023. In this study, we describe efforts made to encourage donation from newly eligible people and the resulting donation gain. Materials and Methods Actions targeted individual donors deferred after 1 January 2012. Marketing included website, social media and general advertising. Staff asked first‐time donors if the criteria change had motivated their donation. Deferred and returning donor data were determined from our donor database.

Results

In the 12 months post‐implementation, 12.8% of first‐time donors surveyed were newly eligible ( n = 8667) and 7.8% of vCJD risk deferred donors returned ( n = 5159). Eighty‐five percent of deferrals occurred pre‐2017; the return rate was 6.5% in this group. The highest return rate (24%) occurred in donors deferred after 2020.

Conclusion

Removal of the vCJD deferrals had a major positive impact. The greatest gain was in new donors who had previously self‐deferred. Despite intensive efforts, only one‐quarter of recently deferred donors returned.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Creutzfeldt-Jakob SyndromeBlood DonorsDonor SelectionHumansMaleUnited KingdomFemaleFranceMiddle AgedIreland

Stichwörter der Autor:innen

blood donorsemerging pathogensvCJD

Autor:innen und Institutionen

  • Canadian Blood Services, Medical Affairs and Innovation, Ottawa, Ontario, Canada.
  • Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Canadian Blood Services, Enterprise Program Management, Toronto, Ontario, Canada.
  • Canadian Blood Services, Operational Excellence, Ottawa, Ontario, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

ORCID-Profile: Mindy Goldman, Sheila F O'Brien

Zitieren

APA

Goldman, M., McKee, D., Smith, S., & O'Brien, S. F. (2025). Removal of deferrals for variant Creutzfeldt–Jakob disease risk: Impact on new and previously deferred donors. Vox Sanguinis, 120(6), 635-638. https://doi.org/10.1111/vox.70021

Vancouver

Goldman M, McKee D, Smith S, O'Brien SF. Removal of deferrals for variant Creutzfeldt–Jakob disease risk: Impact on new and previously deferred donors. Vox Sanguinis. 2025;120(6):635-638. doi:10.1111/vox.70021

BibTeX
@article{Goldman2025,
  author = {Goldman, Mindy and McKee, David and Smith, Shane and O'Brien, Sheila F},
  title = {Removal of deferrals for variant Creutzfeldt–Jakob disease risk: Impact on new and previously deferred donors},
  journal = {Vox Sanguinis},
  year = {2025},
  volume = {120},
  number = {6},
  pages = {635--638},
  doi = {10.1111/vox.70021}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche